Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
1, 2 dithiolane 3 valeric acid · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Alpha lipoic acid 600 mg | ACTIVE_COMPARATOR | - |
| placebo pill | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| 1,2 dithiolane 3 valeric acid | DRUG | 600 mg alpha lipoic acid per day |
Inclusion Criteria: * Diabetes type II, mild non proliferative diabetic retinopathy, * Microalbuminuria \> 30 mg/L Exclusion Criteria: Ophthalmic exclusion criteria * severe non-proliferative or proliferative diabetic retinopathy * Macular edema * Eye diseases interfering with the examinations o...
1,2 dithiolane 3 valeric acid is being studied for use in diabetes mellitus, specifically for diabetic macular edema, a complication of diabetes that affects the eyes. It is a small molecule being developed as a potential treatment for this condition.
The specific molecular target of 1,2 dithiolane 3 valeric acid is not disclosed in available information. It is a small molecule being investigated for its potential effects in diabetic macular edema, but its mechanism of action has not been publicly detailed.
1,2 dithiolane 3 valeric acid is being developed by Bausch + Lomb Corporation, a company traded on the stock exchange under the ticker symbol BLCO. The company is conducting clinical research on this compound for diabetic macular edema.
1,2 dithiolane 3 valeric acid is in Phase 3 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and efficacy.
1,2 dithiolane 3 valeric acid has been studied in a Phase 3 clinical trial registered as NCT01208948, titled "Clinical Trial on Alpha Lipoic Acid in Diabetic Macular Edema." This completed trial enrolled 520 participants with diabetes mellitus and macular edema in Germany.
1,2 dithiolane 3 valeric acid is also known as alpha lipoic acid. The clinical trial NCT01208948 refers to the compound as alpha lipoic acid, indicating that these names refer to the same substance being studied for diabetic macular edema.